Continuous Pharmaceutical Manufacturing Market (2026-2036)

The growth of this market is mainly driven by strong support from regulators, including the International Council for Harmonisation's Q13 guideline on continuous manufacturing and the U.S. Food and Drug Administration's Advanced Manufacturing Technologies Designation Program, the need to reduce drug shortages and strengthen domestic supply chains, the lower cost, smaller footprint, and faster development timelines that continuous processes offer compared with batch production, the growth of high-value and high-potency drugs that benefit from contained and consistent processing, the adoption of continuous bioprocessing for biologics, and advances in process analytical technology and digital process control. However, factors such as high upfront investment and the cost of replacing existing batch facilities, the technical complexity of developing and validating continuous processes, the shortage of skilled engineers, and the limited flexibility of dedicated lines for low-volume products are expected to restrain the growth of this market to some extent.

Continuous pharmaceutical manufacturing is a production approach in which raw materials are fed into a process and products are removed from it continuously, rather than being made in separate batches with stops between each step. In drug product manufacturing, continuous lines connect feeding, blending, granulation, drying, compression, and coating into a single integrated process for tablets and capsules. In drug substance manufacturing, flow chemistry reactors carry out chemical reactions in continuously flowing streams, which allows better control of temperature, mixing, and hazardous reactions. In biologics manufacturing, continuous bioprocessing uses perfusion cell culture and continuous chromatography to produce proteins and antibodies with higher productivity in smaller facilities. Continuous processes are monitored in real time with process analytical technology (PAT) and controlled by advanced software, which allows quality to be built into the process rather than tested at the end.

This market covers the global revenue from equipment, systems, and software used for continuous pharmaceutical manufacturing, measured in value. It includes integrated continuous manufacturing systems, continuous unit operation equipment such as loss-in-weight feeders, continuous blenders, twin-screw granulators, and continuous dryers, continuous bioprocessing systems, process analytical technology and control software, and flow chemistry reactors. It is segmented by product type, molecule type, application, end user, and geography. Batch manufacturing equipment, general laboratory instruments, and contract manufacturing service revenue are not included.

The pharmaceutical industry has relied on batch manufacturing for decades, and most existing plants are built around it. In batch processes, each step is carried out separately, materials are held and tested between steps, and products are released only after laboratory testing of finished batches. This approach is well understood and flexible, but it requires large facilities, long cycle times, and large inventories, and scaling up from development to commercial production often requires new equipment and additional validation. Quality problems in batch processes can lead to rejected batches, recalls, and drug shortages.

Continuous manufacturing offers several important advantages over traditional batch production for both drug substances and drug products. Production can be scaled by running the process for longer rather than building larger equipment, which shortens development timelines and reduces the risk of scale-up problems. Continuous facilities are much smaller than batch facilities, which reduces capital and operating costs. Real-time monitoring and control improve product consistency and allow real-time release testing in some cases. Continuous processes also reduce the amount of material in process at any time, which improves safety when handling hazardous reactions or highly potent compounds, and they reduce waste and energy use.

The economics of continuous manufacturing have been studied extensively by industry and academic groups, and published analyses have found that continuous processes can reduce capital costs, operating costs, and facility footprints significantly compared with equivalent batch facilities, depending on the product and process. These savings, combined with faster development and more consistent quality, are the main reasons why large pharmaceutical companies have built continuous capabilities.

Regulators in the U.S., Europe, and Japan have strongly supported the adoption of continuous manufacturing. The FDA has encouraged its adoption for more than a decade through its Emerging Technology Program, and the ICH Q13 guideline, adopted in 2022, provides a harmonized framework for continuous manufacturing across the U.S., Europe, Japan, and other regions. The FDA's Advanced Manufacturing Technologies Designation Program, finalized in 2025, offers additional support. Governments also see continuous and advanced manufacturing as a way to bring drug production back to domestic markets and reduce dependence on overseas suppliers.

The market includes a range of equipment, bioprocessing, and technology suppliers with different areas of focus. GEA, Glatt, L.B. Bohle, Fette Compacting, Korsch, Gericke, Coperion, and Hosokawa Micron supply continuous oral solid dosage equipment and integrated lines. Thermo Fisher Scientific offers continuous processing equipment, such as twin-screw granulators and extruders. Corning supplies flow chemistry reactors, while Sartorius, Cytiva, Repligen, and Merck KGaA supply continuous bioprocessing systems. Siemens supplies process control and PAT software that integrates continuous lines.

Over the forecast period, the continuous pharmaceutical manufacturing market is expected to grow strongly, supported by regulatory incentives, supply chain investment, and technology advances. North America is expected to remain the largest market, while Asia-Pacific is expected to grow fastest as manufacturers in China, India, Japan, and South Korea invest in advanced manufacturing.

Perfusion and continuous purification let us produce more antibody in a smaller plant, which is essential when we compete on price.

This explains why continuous bioprocessing systems form the fastest-growing product type and why biologics are growing faster than small molecules.

Continuous lines make sense for our high-volume products, but the investment and regulatory work mean we move one product at a time.

This shows why converting existing products remains slow and why most demand comes from new facilities and new products, while generic manufacturers adopt continuous processes selectively for their highest-volume medicines.

Small molecules are expected to account for the largest share of the market in 2026, while biologics are projected to register the higher CAGR, driven by continuous bioprocessing.

ICH Q13 is an international guideline adopted in November 2022 that describes the scientific and regulatory considerations for developing, implementing, and registering continuous manufacturing processes for drug substances and drug products. The FDA published it as final guidance in March 2023.

Drug product manufacturing is expected to account for the largest share of the market in 2026, while API and drug substance manufacturing is projected to register the higher CAGR, driven by flow chemistry and continuous biologics production.

Continuous manufacturing can reduce facility size and costs, shorten development and production times, improve product consistency through real-time monitoring and control, reduce waste and energy use, and improve safety when handling hazardous or highly potent materials.

It is an FDA program, with final guidance published in January 2025, that allows qualifying advanced manufacturing technologies, such as some continuous processes, to receive designation, which provides early engagement with the FDA and expedited assessment of applications that use them.